Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1)

被引：52
作者：
Harvey, Ruth [1 ]
Wheeler, Jun X. [2 ]
Wallis, Chantal L. [1 ]
Robertson, James S. [1 ]
Engelhardt, Othmar G. [1 ]
机构：
[1] Natl Inst Biol Stand & Controls, Blanche Lane, Div Virol, Potters Bar EN6 3QG, Herts, England
[2] Natl Inst Biol Stand & Controls, Blanche Lane, Mol Struct Lab, Potters Bar EN6 3QG, Herts, England
来源：
VACCINE | 2008年 / 26卷 / 51期
基金：
英国医学研究理事会;
关键词：
Influenza; Vaccine; Haemagglutinin;
D O I：
10.1016/j.vaccine.2008.09.050
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The assessment of potential candidate influenza vaccine viruses includes a number of factors. Growth properties of the Virus and yield of antigen, specifically the haemagglutinin (HA), are of key importance. The recently developed H5N1 candidate vaccine Virus NIBRG-14 (with HA and NA genes derived from the clade 1 virus A/Viet Nam/1194/2004 in an A/Puerto Rico/8/34 background) has been Suggested to yield low amounts of antigen. While investigating the antigen yield of H5N1 vaccine Viruses, we found that accurate quantitation of the HA content of some H5N1 Viruses was difficult due to the migration characteristics of the proteins on SDS-PAGE gels. The HA1 and HA2 hands co-migrated with nucleoprotein (NP) and matrix Protein (M1) respectively, preventing accurate analysis. We have developed an accurate way of quantitating HA from these H5N1 viruses by introducing a deglycosylation step to the standard protocol. Using this method, we showed reproducibly that the low yield of NIBRG-14 is, at least in part, due to a lower than usual content of HA in Virus preparations. This was also found to be the case for the parent wild type A/Viet Nam/1194/2004 virus. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6550 / 6554
页数：5
相关论文
共 12 条
[1]  
Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
[2]   Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].
Bresson, Jean-Louis ;
Perronne, Christian ;
Launay, Odile ;
Gerdil, Catherine ;
Saville, Melanie ;
Wood, John ;
Hoeschler, Katja ;
Zambon, Maria C. .
LANCET, 2006, 367 (9523) :1657-1664
[3]   Enhanced growth of seed viruses for H5N1 influenza vaccines [J].
Horimoto, Taisuke ;
Murakami, Shin ;
Muramoto, Yukiko ;
Yamada, Shinya ;
Fujii, Ken ;
Kiso, Maki ;
Iwatsuki-Horimoto, Kiyoko ;
Kino, Yolchiro ;
Kawaoka, Yoshihiro .
VIROLOGY, 2007, 366 (01) :23-27
[4]   Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape [J].
Jin, H ;
Leser, GP ;
Zhang, J ;
Lamb, RA .
EMBO JOURNAL, 1997, 16 (06) :1236-1247
[5]  
KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643
[6]   Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial [J].
Leroux-Roels, Isabel ;
Borkowski, Astrid ;
Vanwolleghem, Thomas ;
Drame, Mamadou ;
Clement, Frederic ;
Hons, Eliane ;
Devaster, Jeanne-Marie ;
Leroux-Roels, Geert .
LANCET, 2007, 370 (9587) :580-589
[7]   Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system [J].
Nicolson, C ;
Major, D ;
Wood, JA ;
Robertson, JS .
VACCINE, 2005, 23 (22) :2943-2952
[8]   Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics [J].
Subbarao, K ;
Chen, HL ;
Swayne, D ;
Mingay, L ;
Fodor, E ;
Brownlee, G ;
Xu, XY ;
Lu, XH ;
Katz, J ;
Cox, N ;
Matsuoka, Y .
VIROLOGY, 2003, 305 (01) :192-200
[9]   Characterization of the Protein Content of a Meningococcal Outer Membrane Vesicle Vaccine by Polyacrylamide Gel Electrophoresis and Mass Spectrometry [J].
Vipond, Caroline ;
Wheeler, Jun X. ;
Jones, Christopher ;
Feavers, Ian M. ;
Suker, Janet .
HUMAN VACCINES, 2005, 1 (02) :80-84
[10]  
*WHO, 2005, WHO H5N1 AV INFL VAC
12